Aim To evaluate the relationship between cardiovascular remodelling and glomerular filtration rate (eGFR) in pre-dialysis chronic kidney disease (CKD) patients without cardiovascular diseases (CVD) and in renal transplant recipients (RTR). Methods The cross-sectional study included 83 patients with eGFR<60 mL/min/1.73m 2 (45 with CKD 3 stage and 38 with CKD 4 stage). Thirty six RTR had eGFR 67.8 (57.3-73.7) mL/ min/1.73m 2 and control group consisted of 44 patients with eGFR>60 mL/min/1.73m 2. All patients were evaluated by echocardiography and X-ray. Results Left ventricular hypertrophy (LVH) was present in 74.7% CKD patients, most frequently in CKD 4 stage and in RTR. Calcifications of abdominal aorta (CAA) were present in 87% CKD 4, 60% RTR and in 44% CKD 3 patients. Calcifications of the mitral valve were found in 34.2% CKD 4, 25.0% RTR and in 6.7% CKD 3 stage patients. Aortic valve calcifications were most frequently present in CKD 4 stage (26.3%). The LV mass index negatively correlated with eGFR (p<0.001), and positively with parathyroid hormone (p<0.001), phosphorus (p=0.043), age (p<0.001) and diabetes (p=0.043). In multivariate regression analysis the risk factor for calcifications of the mitral and aortic valve, as well as for CAA was the decline in eGFR (p<0.001). Conclusion Renal transplant recipients have a higher incidence of CV remodelling than patients with CKD 3 and less than patients with CKD 4 stage, indicating incomplete regression of CV calcifications and LVH after kidney transplantation. A decrease of renal function represents a significant risk factor for valvular and vascular calcifications occurrence in CKD patients.
Park K, Chang J, Kim T, Kim H, Lee E, Kim H, et al. Lower concentrations of serum phsphorus within the normal range could be associated with less calcification of the coronary artery in Koreans with normal renal function. Am J Clin Nutr 2011:1465–70.
2
Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P, et al. Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group. European Society of Cardiology J Am Soc Echocardiogr 2005:1440–63.
3
Bayauli M, Lepira F, Kayembe P, ’buyamba-Kabangu M, J. Left ventricular hypertrophy and geometry in type 2 diabetes patients with chronic kidney disease. An echocardiographic study. Cardiovasc J Afr 2012:73–7.
4
Matsushita K, Kwak L, Sang Y, Ballew S, Skali H, Shah A, et al. Kidney disease measures and left ventricular structure and function: the atherosclerosis risk in communities study. J Am Heart Assoc 2017:6259.
5
Ali T, Idrees M, Shoukat, Akhtar S. Left ventricular hypertrophy among predialysis chronic kidney disease patients: Sindh institute of urology and transplantation experience. Saudi J Kidney Dis Transpl 2017:1375–80.
6
Shenasa M, Shenasa H. Hypertension, left ventricular hypertrophy, and sudden cardiac death. Int J Cardiol 2017:60–3.
7
Chen S, Huang J, Su H, Chiu Y, Chang J, Hwang S, et al. Prognostic cardiovascular markers in chronic kidney disease. Kidney Blood Press Res 2018:1388–407.
8
Urena-Torres P, Vervloet M, Mazzaferro S, Oury F, Brandenburg V, Bover J, et al. ERA-EDTA CKD-MBD Working Group. Novel insights into parathyroid hormone: report of the parathyroid day in chronic kidney disease. Clin Kidney J 2018.
9
Vervloet M, Van Ballegooijen A. Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney International 2018:1060–72.
10
Kauppila L, Polak J, Cupples L, Hannan M, Kiel D, Wilson P. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 1997:245–50.
11
Custidio M, Koike M, Neves, Reis L, Graciolli F, Neves C, et al. Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. Nephrol Dial Transplant 2012:1437–45.
12
Rebić D, Rašić S. Cardiovascular remodelling in chronic kidney disease. EMJ Neph 2014:113–9.
13
Benz K, Hilgers K, Daniel C, Amann K. Vascular calcification in chronic kidney disease: the role of inflammation. Int J Nephrol 2018:4310379.
14
Paloian N, Giachelli C. A current understanding of vascular calcification in CKD. Am J Physiol Renal Physiol 2014:891–900.
15
Fox C, Larson M, Vasanrs, Guo C, Parise H, Levy D, et al. Cross-sectional association of kidney function with valvular and annular calcification: the Framingham heart study. J Am Soc Nephrol 2006:521–7.
16
Rong S, Qiu X, Shang J, Huang M, Tang Y, Yuan Z, et al. Risk factors for heart valve calcification in chronic kidney disease. Medicine (Baltimore) 2018:9804.
17
Leskinen Y, Paana T, Saha H, Groundstroem K, Lehtimaki T, Kilpinen S, et al. Valvular calcification and its relationship to atherosclerosis in chronic kidney disease. J Heart Valve Dis 2009:429–38.
18
Hill N, Fatoba S, Oke J, Hirst J, ’callaghan O, Lasserson C, et al. Global prevalence of chronic kidney disease -a systematic review and meta-analysis. PLoS One 2016:158765.
19
KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013:1–150.
20
Levey A, Coresh J, Greene T, Marsh J, Stevens L, Kusek J, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007:766–72.
21
Peeters M, Van Den Brand J, Van Zuilen A, Koster Y, Bots M, Vervloet M, et al. Wetzels JFM and For the MASTERPLAN Study Group. Abdominal aortic calcification in patients with CKD. J Nephrol 2017:109–18.
22
Kim I, Kim M, Lee D, Lee S, Shin M, Rhee H, et al. Cardiac valve calcification is associated with presence and severity of coronary artery disease in patients with pre-dialysis chronic kidney disease. Clin Exp Nephrol 2015:1090–7.
23
Gluba-Brzozka A, Michalska-Kasiczak M, Franczyk-Skora B, Nocun M, Banach M, Rysz J. Markers of increased cardiovascular risk in patients with chronic kidney disease. Lipids Health Dis 2014:135.
24
Byon C, Chen Y. Molecular mechanisms of vascular calcification in chronic kidney disease: the link between bone and the vasculature. Curr Osteopor Rep 2015:206–15.
25
Wang Y, Osborne M, Tung B, Li M, Li Y. Imaging cardiovascular calcification. J Am Heart Assoc 2018:8564.
26
Porter C, Stavroulopoulos A, Roe S, Pointon K, Cassidy M. Detection of coronary and peripheral artery calcification in patients with chronic kidney disease stages 3 and 4, with and without diabetes. Nephrol Dial Transplant 2007:3208–13.
27
Gorriz J, Molina P, Cerveron M, Vila R, Bover J, Nieto J, et al. Vascular calcification in patients with nondialysis CKD over 3 years. Clin J Am Soc Nephrol 2015:654–66.
28
Paoletti E, Nicola D, Gabbai L, Chiodini F, Ravera P, Pieracci M, et al. Associations of left ventricular hypertrophy and geometry with adverse outcomes in patients with CKD and hypertension. Clin J Am Soc Nephrol 2016:271–9.
29
Park M, Hsu C, -Y, Li Y, Mishra R, Keane M, et al. Chronic Renal Insufficiency Cohort (CRIS) Study Group. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol 2012:1725–34.
30
Massicotte-Azarniouch, David, Carrero J, Lam N, Molnar A, Zimmerman D, et al. Incident atrial fibrillation and the risk of congestive heart failure, myocardial infarction, end-stage kidney disease, and mortality among patients with a decreased estimated GFR. Am J Kidney Dis 2018:191–9.
31
Nitta K, Iimuro S, Imai E, Matsuo S, Makino H, Akizawa T, et al. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study. Clin Exp Nephrol 2019:85–98.
32
Pluta A, Stroeecki P, Krintus M, Odrowaz-Sypniewska G, Manitius J. Left ventricular remodeling and arterial remodeling in patients with chronic kidney disease stage 1-3. Ren Fail 2015:1105–10.
33
El Hafeez A, Bolignano S, D, ’arrigo D, Dounousi G, Tripepi E, et al. Prevalence and burden of chronic kidney disease among the general population and high-risk groups in Africa: a systematic review. BMJ Open 2018:15069.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
